Drug Shortage Report for ROPIVACAINE HYDROCHLORIDE INJECTION, USP
Report ID | 158789 |
Drug Identification Number | 02439409 |
Brand name | ROPIVACAINE HYDROCHLORIDE INJECTION, USP |
Common or Proper name | Ropivacaine Hydrochloride Injection |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | ROPIVACAINE HYDROCHLORIDE |
Strength(s) | 10MG |
Dosage form(s) | SOLUTION |
Route of administration | EPIDURAL EPIDURAL |
Packaging size | 10 mL |
ATC code | N01BB |
ATC description | ANESTHETICS, LOCAL |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2022-03-01 |
Estimated end date | Unknown |
Actual end date | 2022-08-31 |
Shortage status | Resolved |
Updated date | 2022-09-01 |
Company comments | Effective May 2, 2022, contract customers will be allocated 100% of 10mL demand plus 50% of 20mL demand on a mL:mL basis. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v6 | 2022-09-01 | French | Compare |
v5 | 2022-09-01 | English | Compare |
v4 | 2022-05-02 | French | Compare |
v3 | 2022-05-02 | English | Compare |
v2 | 2022-04-13 | French | Compare |
v1 | 2022-04-13 | English | Compare |
Showing 1 to 6 of 6